Citius Pharmaceuticals Inc (CTXR)vsMerck & Company Inc (MRK)
CTXR
Citius Pharmaceuticals Inc
$0.53
-1.40%
HEALTHCARE · Cap: $14.69M
MRK
Merck & Company Inc
$144.52
-2.23%
HEALTHCARE · Cap: $362.27B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 948191% more annual revenue ($67.38B vs $7.11M). MRK leads profitability with a 3.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 42/100 (D).
CTXR
Avoid30
out of 100
Grade: F
MRK
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CTXR.
Margin of Safety
-74.0%
Fair Value
$84.93
Current Price
$144.52
$59.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Strong operational efficiency at 35.2%
Generating 5.5B in free cash flow
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
4.7% revenue growth
ROE of 5.5% — below average capital efficiency
3.6% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : CTXR
The strongest argument for CTXR centers on Price/Book, Debt/Equity.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : CTXR
The primary concerns for CTXR are Revenue Growth, EPS Growth, Market Cap.
Bear Case : MRK
The primary concerns for MRK are Revenue Growth, Return on Equity, Profit Margin. A P/E of 148.4x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
CTXR carries more volatility with a beta of 1.04 — expect wider price swings.
MRK is growing revenue faster at 4.7% — sustainability is the question.
MRK generates stronger free cash flow (5.5B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (42/100 vs 30/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Citius Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets critical care products. The company is headquartered in Cranford, New Jersey.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?